[go: up one dir, main page]

TN2013000393A1 - Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase - Google Patents

Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase

Info

Publication number
TN2013000393A1
TN2013000393A1 TNP2013000393A TN2013000393A TN2013000393A1 TN 2013000393 A1 TN2013000393 A1 TN 2013000393A1 TN P2013000393 A TNP2013000393 A TN P2013000393A TN 2013000393 A TN2013000393 A TN 2013000393A TN 2013000393 A1 TN2013000393 A1 TN 2013000393A1
Authority
TN
Tunisia
Prior art keywords
acetyl
coa carboxylase
pyrazolospirocetone
inhibitors
derivatives
Prior art date
Application number
TNP2013000393A
Other languages
English (en)
Inventor
David Andrew Griffith
Robert Lee Dow
James Alfred Southers Jr
David James Edmonds
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TN2013000393A1 publication Critical patent/TN2013000393A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Photographic Processing Devices Using Wet Methods (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

L'invention propose un composé de formule (I) ou un de ses sels pharmaceutiquement acceptables associés; dans laquelle G représente (II) ou (III); R1, R2 et R3 sont tels que décrite ici; leurs compositions pharmaceutiques associées; et leur utilisation associée dans le traitement de maladies, états ou troubles modulés par l'inhibition d'une (d') enzyme (s) acétyl-CoA carboxylase chez un animal.
TNP2013000393A 2011-04-22 2013-09-27 Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase TN2013000393A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478240P 2011-04-22 2011-04-22
PCT/IB2012/051732 WO2012143813A1 (fr) 2011-04-22 2012-04-09 Dérivés de pyrazolospirocétone destinés à être utilisés comme inhibiteurs d'acétyl-coa carboxylase

Publications (1)

Publication Number Publication Date
TN2013000393A1 true TN2013000393A1 (fr) 2015-01-20

Family

ID=46025823

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000393A TN2013000393A1 (fr) 2011-04-22 2013-09-27 Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase

Country Status (42)

Country Link
US (4) US8802688B2 (fr)
EP (1) EP2699576B1 (fr)
JP (1) JP5657174B2 (fr)
KR (1) KR101567659B1 (fr)
CN (2) CN103492388A (fr)
AP (1) AP3499A (fr)
AR (1) AR086198A1 (fr)
AU (1) AU2012245996B2 (fr)
CA (1) CA2831380C (fr)
CL (1) CL2013002794A1 (fr)
CO (1) CO6801757A2 (fr)
CR (1) CR20130464A (fr)
CU (1) CU24164B1 (fr)
CY (1) CY1117122T1 (fr)
DK (1) DK2699576T3 (fr)
DO (1) DOP2013000243A (fr)
EA (1) EA022375B1 (fr)
EC (1) ECSP13013038A (fr)
ES (1) ES2561452T3 (fr)
GE (1) GEP20166474B (fr)
GT (1) GT201300258A (fr)
HR (1) HRP20151397T1 (fr)
HU (1) HUE028602T2 (fr)
IL (1) IL228949A (fr)
MA (1) MA35061B1 (fr)
ME (1) ME02312B (fr)
MX (1) MX348860B (fr)
MY (1) MY162167A (fr)
NI (1) NI201300111A (fr)
NZ (1) NZ616156A (fr)
PE (1) PE20141187A1 (fr)
PH (1) PH12013501941A1 (fr)
PL (1) PL2699576T3 (fr)
PT (1) PT2699576E (fr)
RS (1) RS54526B1 (fr)
SG (1) SG194142A1 (fr)
SI (1) SI2699576T1 (fr)
TN (1) TN2013000393A1 (fr)
TW (1) TWI464171B (fr)
UA (1) UA107753C2 (fr)
UY (1) UY34027A (fr)
WO (1) WO2012143813A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2947082A1 (fr) * 2009-11-10 2015-11-25 Pfizer Inc INHIBITEURS DE N1-PYRAZOLOSPIROCÉTONE ACÉTYL-CoA CARBOXYLASE
CN102491974B (zh) * 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
WO2014149819A1 (fr) 2013-03-14 2014-09-25 Kalyra Pharmaceuticals, Inc. Composés analgésiques bicycliques
AU2014262636A1 (en) * 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
KR20160006762A (ko) 2013-05-10 2016-01-19 님버스 아폴로, 인코포레이티드 Acc 억제제 및 이의 용도
AU2014262547A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
HK1217448A1 (zh) 2013-09-12 2017-01-13 辉瑞大药厂 乙酰辅酶a羧化酶抑制剂用於治疗寻常痤疮的用途
EP3670496A3 (fr) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Inhibiteurs de acc2
JP6542794B2 (ja) * 2013-12-12 2019-07-10 ゼノ ロイアルティー アンド マイルストーンズ リミテッド ライアビリティー カンパニー 二環式アルキル化合物、および合成
CN113336653A (zh) * 2014-03-07 2021-09-03 里科瑞尔姆Ip控股有限责任公司 螺桨烷衍生物及合成
US10457502B2 (en) 2014-05-22 2019-10-29 Symbotic Canada Ulc Tool and method for layer depalletizing
CA2961605C (fr) 2014-09-17 2023-01-10 Kalyra Pharmaceuticals, Inc. Composes bicycliques
CA3010097C (fr) * 2015-12-31 2023-08-22 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Application de triacetyl-3-hydroxyphenyladenosine dans la preparation de medicament pharmaceutique destine a la prevention ou au traitement de steatose hepatique non alcoolique
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
WO2018213140A1 (fr) 2017-05-15 2018-11-22 Zeno Royalties & Milestones, LLC Composés analgésiques
MX392203B (es) 2017-11-21 2025-03-21 Pfizer Sal cristalina de 2-amino-2-(hidroximetil)propano-1,3-diol de acido 4-(4-(1-isopropil-7-oxo-1,4,6,7-tetrahidrospiro[indazol-5,4'-piperidina]-1'-carbonil)-6-metoxipiridin-2-il)benzoico
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
WO2024140923A1 (fr) * 2022-12-30 2024-07-04 苏州浦合医药科技有限公司 Inhibiteur de prmt5-mta
WO2024213044A1 (fr) * 2023-04-14 2024-10-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Dérivés de cycles fusionnés azacyclo-carbonyle et leur utilisation
WO2025036472A1 (fr) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Inhibiteur de prmt5 mta-coopératif spirocyclique

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
WO2002068388A2 (fr) 2001-02-28 2002-09-06 Merck & Co., Inc. Derives de piperidine acylee tels que les agonistes du recepteur 4 de la melanocortine
PL372887A1 (en) 2002-02-27 2005-08-08 Pfizer Products Inc. Acc inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
JP4227660B2 (ja) 2004-05-12 2009-02-18 ファイザー・プロダクツ・インク ジペプチジルペプチダーゼｉｖインヒビターとしてのプロリン誘導体およびそれらの使用
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
EP1753766A1 (fr) 2004-05-25 2007-02-21 Pfizer Products Inc. Derives de tetraazabenzo(e)azulene et analogues de ceux-ci
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
MX2008000966A (es) 2005-07-19 2008-03-26 Merck & Co Inc Nuevos derivados de espirocromanona.
JPWO2007013691A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 スピロ環化合物
ATE493412T1 (de) 2005-11-18 2011-01-15 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
SI2463283T1 (sl) 2006-04-20 2014-09-30 Pfizer Products Inc. Kondezirane fenil amino heterociklične spojine za preprečevanje in zdravljenje bolezni, ki jih posreduje glukokinaza
US20090270435A1 (en) 2006-11-29 2009-10-29 Jeffrey Wayne Corbett Spiroketone Acetyl-CoA Carboxylase Inhibitors
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
EP2123652A1 (fr) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Composé hétérocyclique
CN101675052A (zh) 2007-04-12 2010-03-17 辉瑞大药厂 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
JP2011521940A (ja) 2008-05-28 2011-07-28 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
ES2545231T3 (es) 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
WO2010002010A1 (fr) * 2008-07-04 2010-01-07 Banyu Pharmaceutical Co.,Ltd. Nouveaux acides spirochromanone carboxyliques
US8110570B2 (en) 2008-07-14 2012-02-07 Cropsolution, Inc. Modulators of acetyl-coenzyme A carboxylase and methods of use thereof
US20110130365A1 (en) 2008-07-29 2011-06-02 Benbow John W Fluorinated Heteroaryls
BRPI0918841B8 (pt) 2008-08-28 2021-05-25 Pfizer derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
WO2010086820A1 (fr) 2009-02-02 2010-08-05 Pfizer Inc. Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle
EP2406230A1 (fr) 2009-03-11 2012-01-18 Pfizer Inc. Indazole amides substitués
CN102388038B (zh) 2009-03-11 2014-04-23 辉瑞大药厂 用作葡糖激酶活化剂的苯并呋喃基衍生物
JP2012520868A (ja) 2009-03-20 2012-09-10 ファイザー・インク ３−オキサ−７−アザビシクロ［３．３．１］ノナン
CA2759843A1 (fr) 2009-05-08 2010-11-10 Pfizer Inc. Modulateurs de gpr119
US20120052130A1 (en) 2009-05-08 2012-03-01 Pfizer Inc. Gpr 119 modulators
CN102459222B (zh) 2009-06-05 2014-06-04 辉瑞大药厂 用作gpr119 调节剂的l-(哌啶-4-基)-吡唑衍生物
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
WO2011058473A1 (fr) * 2009-11-10 2011-05-19 Pfizer Inc. Inhibiteurs de n2-pyrazolospirocétone acétyl-coa carboxylase
EP2947082A1 (fr) * 2009-11-10 2015-11-25 Pfizer Inc INHIBITEURS DE N1-PYRAZOLOSPIROCÉTONE ACÉTYL-CoA CARBOXYLASE
HUE031616T2 (hu) * 2010-09-30 2017-07-28 Pfizer N1-pirazol-spiroketon acetil-koenzim-A karboxiláz inhibítorok

Also Published As

Publication number Publication date
NI201300111A (es) 2014-02-12
US20140323730A1 (en) 2014-10-30
MX348860B (es) 2017-06-30
GT201300258A (es) 2015-06-02
PH12013501941A1 (en) 2021-06-23
CA2831380A1 (fr) 2012-10-26
EP2699576A1 (fr) 2014-02-26
EA022375B1 (ru) 2015-12-30
US20150336958A1 (en) 2015-11-26
TWI464171B (zh) 2014-12-11
JP2014515755A (ja) 2014-07-03
HUE028602T2 (hu) 2016-12-28
MY162167A (en) 2017-05-31
DK2699576T3 (en) 2016-02-15
CO6801757A2 (es) 2013-11-29
KR20140015511A (ko) 2014-02-06
PE20141187A1 (es) 2014-09-18
JP5657174B2 (ja) 2015-01-21
MA35061B1 (fr) 2014-04-03
EA201391288A1 (ru) 2014-04-30
CU24164B1 (es) 2016-03-31
IL228949A0 (en) 2013-12-31
CA2831380C (fr) 2016-04-05
US8802688B2 (en) 2014-08-12
UY34027A (es) 2013-04-05
AU2012245996B2 (en) 2016-09-01
PL2699576T3 (pl) 2016-05-31
AP2013007129A0 (en) 2013-09-30
RS54526B1 (sr) 2016-06-30
CU20130126A7 (es) 2014-01-29
SI2699576T1 (sl) 2016-02-29
TW201305162A (zh) 2013-02-01
DOP2013000243A (es) 2013-12-31
CN106117205B (zh) 2018-09-21
ES2561452T3 (es) 2016-02-26
HRP20151397T1 (hr) 2016-01-15
NZ616156A (en) 2014-08-29
MX2013012313A (es) 2014-01-31
CN106117205A (zh) 2016-11-16
AR086198A1 (es) 2013-11-27
AU2012245996A1 (en) 2013-10-03
PT2699576E (pt) 2016-03-09
WO2012143813A1 (fr) 2012-10-26
EP2699576B1 (fr) 2015-12-09
IL228949A (en) 2016-11-30
SG194142A1 (en) 2013-11-29
CR20130464A (es) 2013-10-16
CN103492388A (zh) 2014-01-01
US20150112068A1 (en) 2015-04-23
GEP20166474B (en) 2016-05-10
ME02312B (me) 2016-06-20
AP3499A (en) 2015-12-31
UA107753C2 (xx) 2015-02-10
KR101567659B1 (ko) 2015-11-09
CY1117122T1 (el) 2017-04-05
CL2013002794A1 (es) 2013-12-27
US20120270893A1 (en) 2012-10-25
ECSP13013038A (es) 2014-01-31

Similar Documents

Publication Publication Date Title
TN2013000393A1 (fr) Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA38461A1 (fr) Inhibiteurs de la voie de la kynurénine
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
MA38138A1 (fr) Dérivés inédits de quinolone
MA38333A1 (fr) Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
EP2796450A4 (fr) Dérivés 6-aminopyridine-3-ol ou leurs sels pharmaceutiquement acceptables, et composition pharmaceutique contenant ces dérivés ou ces sels comme principes actifs pour la prévention ou le traitement des maladies provoquées par l'angiogenèse